Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours ยท Estimated delivery Oct 6 - Oct 11
Retatrutide hits 28% weight loss in Phase 3 A summary of the interesting content that I consumed this past week What I Read This Week: a summary of the content that I consumed this past week Caught My Eye 1) Retatrutide hits 28% weight loss in Phase 3 On May 21, Eli Lilly released Phase 3 results for retatrutide from the 2,339-patient TRIUMPH-1 obesity trial
KDQOL-36 scale scores were significantly (p 0.02 indicated DIF)
This may also increase long-term health risks
Retatrutide is a triple-agonist, meaning it targets three different receptors: the GLP-1 (glucagon-like peptide-1) receptor, the GIP (glucose-dependent insulinotropic polypeptide) receptor, and the GCG (glucagon) receptor.
The initial dose is 10 mcg once daily subcutaneously for 14 days, on the 15 th day the dose is increased to 20 mcg once daily subcutaneously
That's the variable that predicts adherenceand adherence predicts results
US$ 26.68
US$ 21.85
US$ 20.56
US$ 29.62
